Six weeks after a levothyroxine dose increase of 12.5 or 25 mcg a day, a repeat serum thyrotropin (TSH) result tells you whether a patient with primary hypothyroidism has reached target or needs another step. Much of outpatient endocrinology turns on decisions like that: reviewing a fresh lab panel, reading shared continuous glucose monitor (CGM) trends to titrate basal insulin, or stepping up a GLP-1 receptor agonist after four weeks on a starter pen. Each follow-up depends on laboratory results, device data, and a focused clinical history rather than a repeat physical examination. On FutureClinic, you care for those patients by message in an endocrinology clinic under your own name, answering on your own time inside the weekly availability hours you set, while making every medical decision yourself.

Thyroid hormone replacement, lab timing, and when a neck exam is required

Hypothyroidism follow-up centers on laboratory titration and symptom review rather than repeat physical exams. The American Thyroid Association 2014 hypothyroidism guidelines (Jonklaas et al., recommendation 4b) advise adjusting levothyroxine in 12.5 to 25 mcg daily steps with serum TSH measured four to six weeks after any dose change, then checked at four to six months once on target and yearly thereafter. FDA prescribing information for levothyroxine sodium tablets (updated February 2024 and January 2026) specifies checking TSH six to eight weeks after a dose change and every six to 12 months when stable. Ordering the repeat TSH inside the case and adjusting the dose in the same thread keeps titration on schedule. By contrast, patients with a thyroid nodule or goiter need an in-person neck exam and thyroid ultrasound (ATA 2015 guideline, recommendation 6) and are referred for in-person evaluation.

Diabetes follow-up, glucose data, and in-person care boundaries

Routine diabetes care follows a steady rhythm of laboratory checks, glucose data review, and medication adjustments. The American Diabetes Association 2026 Standards of Care recommend testing HbA1c at least twice a year in patients meeting treatment goals and about every three months when therapy changes or glycemic targets are not met (recommendation 6.2), paired with a review of the medication regimen every three to six months (recommendation 9.14). For patients using continuous glucose monitors, the guidelines advise training users to upload or share their data so treatment can be adjusted (recommendation 7.3a). At the same time, the ADA 2026 Standards state that telehealth "should be used to complement and not replace in-person visits" (recommendation 1.3). Foot lesions, retinal exams, and acute metabolic crises require in-person or emergency care.

GLP-1 and tirzepatide titration, safety screening, and prescribing scope

For pharmacologic weight management, the ADA 2026 Standards (recommendation 8.20) and the Endocrine Society 2015 guideline (with its 2026 update in draft) recommend assessing efficacy and safety at least monthly for the first three months after starting an obesity medicine and at least quarterly thereafter. With more than 5% weight loss at three months, therapy should usually continue long term, and the optimal maintenance dose for an individual patient may sit below the maximum approved dose. Semaglutide (Wegovy, revised June 2026) steps up every four weeks from 0.25 mg, and tirzepatide (Zepbound, revised August 2026) increases in 2.5 mg increments at least four weeks apart.

Before prescribing, a clinical history must screen for personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy plans, prior pancreatitis or gallbladder disease, planned surgery or sedation, and insulin or sulfonylurea use. When adding a GLP-1 receptor agonist or tirzepatide, ADA 2026 guidelines advise stopping or reducing sulfonylureas and lowering insulin doses, such as cutting mealtime insulin by 10% to 20% and basal insulin by about 10% if HbA1c is below 7.5%. Acute abdominal pain suggestive of pancreatitis or gallbladder disease needs in-person or emergency care. FutureClinic doctors do not prescribe controlled substances. DailyMed lists no DEA schedule for levothyroxine, liothyronine, metformin, SGLT2 inhibitors, GLP-1 receptor agonists, tirzepatide, and insulin glargine, leaving those medications in scope. Testosterone, stimulants, benzodiazepines, opioids, and scheduled weight-loss or sleep drugs stay out of scope; you choose your interest areas, and FutureClinic's AI screens out controlled substances and flags possible emergencies as unsuitable for care by message.

Clinical trial outcomes and the wait for an endocrinologist

Clinical trials show that asynchronous communication and remote medication titration produce measurable improvements in glycemic control. A systematic review and meta-analysis of 111 randomized trials covering 23,648 adults (Faruque et al., CMAJ 2017) found that telemedicine lowered HbA1c by 0.57 percentage points at three months or less and by 0.28 percentage points at four to 12 months, with the largest reductions occurring where clinicians communicated through web portals or text messaging and adjusted medications. Message-based protocols also support basal insulin titration: in a 12-week randomized controlled trial of 61 patients at Bellevue Hospital (Levy et al., JMIR 2015), weekday text messages of fasting glucose paired with a weekly titration call brought 88% of patients to their target insulin glargine dose, compared with 37% in usual clinic care. In an observational cohort study of 3,778 adults in endocrinology care for type 2 diabetes (Zupa et al., JAMA Network Open 2023), telemedicine-only patients had no 12-month HbA1c change (-0.06 percentage points), whereas in-person and mixed-care patients improved by 0.37 and 0.22 points (the study did not test care by message).

Staying with one doctor matters in a specialty where patients often wait months for a first appointment or live far from a subspecialist. In a 2024 telephone study of 1,032 New York City specialists (Basch et al., JMIR 2024), a new patient with diabetes faced a median wait of 72 days (mean 82 days) to see an endocrinologist, compared with 27 days to see a cardiologist. Access gaps are even wider outside major metropolitan areas: a June 2026 county-level analysis (Chuang et al., 2026) found that about 70% of 2,990 US counties lacked an obesity specialist, defined as an endocrinologist or obesity medicine physician. Caring for patients by message lets people in the states where you are licensed reach you directly and stay with you for follow-up labs and dose changes.

What do remote endocrinology roles ask of a physician?

Job postings read in October 2026 show what remote endocrinology roles ask of a physician and whom they suit:

• Allara Health (65 1099 postings on Ashby, published August 10 to October 9, 2026, across 20 states and Washington, DC): Video visits and patient messages for hormonal and metabolic conditions in women, including PCOS, insulin resistance, and perimenopause. Requires ABIM endocrinology certification or eligibility and at least 10 patient-facing hours a week, with evening-and-weekend variants requiring at least 80% of contracted hours in set windows (evenings 5 to 9 pm, Fridays 8 am to 9 pm, weekends 8 am to 6 pm). Suits endocrinologists wanting scheduled video care in a women's group.
• Form Health (21 postings on Greenhouse, first published July 22 to September 10, 2026): W-2 roles at 32, 36, or 40 hours a week ($210,000 to $250,000 base salary as of September 10, 2026) or part time at 20 hours, with regular video visits, messaging, CGM and pump titration, and advanced practice collaboration. Suits physicians seeking a salaried W-2 team role.
• TeleMed2U (Greenhouse, first published August 19, 2026): Full-time weekday video visits at 37 clinical hours a week, a California license, and advanced practice supervision. Suits doctors wanting full-time weekday video shifts.
• Blue Circle Health (Remotive copy, posted October 10, 2026): Type 1 diabetes telehealth with 60-minute new and 30-minute follow-up visits on fixed hours across 21 states and Washington, DC. Suits specialists wanting scheduled appointment blocks.
• OpenLoop (Ashby, published May 29, 2026): 1099 weight-loss role at 20 to 40-plus hours a week of synchronous and asynchronous visits across three to five state licenses. Suits doctors seeking 20 or more contract hours weekly.

These roles ask for set times on camera, weekly hour minimums, and shifts on someone else's schedule under a company brand. On FutureClinic, there is no video queue, no shift schedule, and no minimum weekly hours. The message thread is the visit itself, answered inside the weekly hours you set in your own time zone, for patients who come to a clinic bearing your name.

Your own endocrinology clinic on FutureClinic

When you open a clinic on FutureClinic, you get your own clinic page and link under your own name to share with anyone. After the first visit, patients stay with you in the same chat for follow-up lab reviews, dose changes, and refills over time, or they can join a monthly membership you offer for unlimited care with you and cancel any time. That ongoing relationship lets you practice the thorough, personal medicine you trained to deliver. You can also send an optional short video or voice note, the Human Signature, so a patient knows you personally took their case.

Before you open a case, FutureClinic's AI works like a chief resident, taking the history, asking the follow-up questions you have trained it to ask, and drafting a reply in your style for you to read, edit, and sign. You make every medical decision, and the AI never gives medical advice by itself. Every FutureClinic doctor a patient sees works from one shared medical record where you order labs with results returned to you, order imaging, prescribe non-controlled medications to the patient's chosen pharmacy with prior authorization help when needed, and view consented outside records and wearable readings from Apple Health, Android's Health Connect, Oura, and Garmin. FutureClinic sells no medicines or products and pays nothing extra for any prescription or test.

You practice as an independent 1099 contractor, setting and changing your own visit and membership prices or seeing people for free. You bring your own patients, or you can pick up cases from an available pool of patients who came to FutureClinic. Starting and leaving are free, with no monthly fees or minimums; FutureClinic keeps 25% of what you charge, covering billing, refunds, monthly payouts, 1099 paperwork, and malpractice coverage from your first case under the FutureClinic Medical Group's $5 million group policy with a $5 million excess layered on top and tail coverage if that policy ends. FutureClinic believes this durable personal connection is the future of healthcare for decades to come. Confirm your NPI in minutes while FutureClinic checks your state licenses: download the FutureClinic Doctors app, or start at https://futureclinic.com/doctors.